How can Germany refuse to cover V with these kinds of results? | AMRN Message Board Posts


Amarin Corporation plc

  AMRN website

AMRN   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  9085 of 9107  at  8/30/2022 5:20:16 PM  by

ex_hacker202


How can Germany refuse to cover V with these kinds of results?

How could any cardio with a high risk patient ignore something like this - not putting them on V is close to malpractice. Is Nissen going to claim MO caused more STEMI's?
 

Announcing new data from its REDUCE-IT study, Ireland-based biotech Amarin Corporation (NASDAQ:AMRN) said Friday that its fish-oil-derived pill Vascepa caused a significant 40% reduction in a severe type of heart attack.

REDUCE-IT is AMRN's global cardiovascular outcomes study that involved more than 8,100 adults with elevated lipid levels and either established cardiovascular disease or diabetes plus risk factors.

The patients were randomized to receive Vascepa (Vazkepa) or placebo over a median follow-up period of 4.9 years.

According to the findings presented at a medical event in Spain, Vascepa, also known as icosapent ethyl (IPE), has led to a significant 40% reduction of ST-segment elevation myocardial infarction (STEMI) compared to placebo (HR=0.60; 95% CI 0.44, 0.81; P=0.0008). STEMI is a more severe type of heart attack with a greater risk of serious complications and death.

IPE is also found to have caused a 27% reduction in non-ST segment elevated myocardial infarction (NSTEMI) (HR=0.73; 95% CI 0.60, 0.89; P=0.001) in addition to clinically important and statistically significant reductions in certain MI subtypes, the company said.

"Importantly, these new data show a significant reduction in the most important type of heart attack known as STEMI, as well as other MI subtypes," remarked Deepak L. Bhatt, a Professor of Medicine at Harvard Medical School and the lead investigator of the study.

 


     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 0  
   Views: 0 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
9086 Re: How can Germany refuse to cover V with these kinds of results? liposghost 1 8/30/2022 6:28:22 PM
9087 Re: How can Germany refuse to cover V with these kinds of results? tastygreenwafers 2 8/31/2022 7:07:19 AM




Financial Market Data provided by
.
Loading...